

Date: 06/11/2018

<p>To,  <b>BSE Limited,</b>  25, P. J. Towers,  Dalal Street,  Mumbai – 400 001  <b>Ref: Company Scrip Code: 532834</b></p>	<p>To,  The Manager,  Listing Department,  <b>National Stock Exchange of India Ltd.,</b>  Exchange Plaza, Bandra Kurla Complex,  Bandra (East), Mumbai- 400051  <b>Ref: Symbol: CAMLINFINE    Series: EQ</b></p>
---	--

**Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - ("SEBI LODR")**

Please find attached herewith the investor presentation on the unaudited financial results of the Company for the quarter and half year ended 30<sup>th</sup> September, 2018 (Q2).

Further, this is to inform you that on 16<sup>th</sup> November, 2018, the senior management team of the Company has scheduled to meet Analysts/Investors in Mumbai as per details below:

Date	Type of meeting	Venue & Time
16 <sup>th</sup> November, 2018	Analysts/Investors meet	Oyster, Hotel Sahara Star, opp. Domestic Airport, Vile Parle, Mumbai from 3:30 pm onwards

We request you to take the above on record and the same be treated as compliance under the applicable Regulations of SEBI LODR.

Note: The date of the scheduled meet is subject to change due to exigencies, if any.

Thanking You,  
Encl.: a/a.  
For **Camlin Fine Sciences Limited**

(Rahul Sawale)  
Group Company Secretary





2018



Unaudited Quarterly Financial Statements  
Q2 FY 2019

November 6, 2018

# Investors' Presentation

# Financial Highlights – Q2 2019 - Consolidated



INR Crores

	Q2 FY 19	Q1 FY 19	Q2 FY 18
Turnover	201.34	181.40	146.14
QoQ $\Delta$ %		10.99%	37.77%
Gross Margin	96.58	93.49	69.27
%age of Turnover	47.97%	51.54%	47.40%
Other Income	9.88	3.80	3.94
EBITDA	17.21	13.89	4.04
%age of Turnover	8.55%	7.66%	2.76%
PBT	9.97	1.66	(6.05)
%age of Turnover	4.95%	0.91%	-4.14%
PAT	1.93	(4.43)	(3.38)
%age of Turnover	0.96%	-2.44%	-2.32%

- Consolidated total revenues for the quarter were at INR 201.34 crore showing a growth of 10.99% & 37.77% as compared to previous quarter and corresponding last year quarter respectively.
- Robust growth in the blends business worldwide and sustained growth in Performance Chemicals has resulted in increase in total revenues.
- In the current quarter PBDIT stood at INR 17.21 crore while Profit after tax was at INR 1.93 crore, an improvement as compared to PBDIT of INR 13.89 crore and negative PAT of INR 4.43 crore.

## Financial Highlights – Q2 2019 – STANDALONE INDIA




	Q2 FY 19	Q1 FY 19	Q2 FY 18
<b>Turnover</b>	<b>118.82</b>	<b>107.85</b>	<b>86.98</b>
<b>QoQ <math>\Delta</math> %</b>		<b>10.17%</b>	<b>36.60%</b>
<b>Gross Margin</b>	<b>32.27</b>	<b>32.14</b>	<b>21.65</b>
<b>%age of Turnover</b>	<b>27.16%</b>	<b>29.80%</b>	<b>24.89%</b>
<b>Other Income</b>	<b>12.71</b>	<b>9.11</b>	<b>3.98</b>
<b>EBITDA</b>	<b>9.52</b>	<b>8.17</b>	<b>(2.07)</b>
<b>%age of Turnover</b>	<b>8.01%</b>	<b>7.57%</b>	<b>-2.38%</b>
<b>PBT</b>	<b>12.78</b>	<b>8.68</b>	<b>(6.09)</b>
<b>%age of Turnover</b>	<b>10.76%</b>	<b>8.05%</b>	<b>-7.00%</b>
<b>PAT</b>	<b>8.09</b>	<b>5.32</b>	<b>(3.67)</b>
<b>%age of Turnover</b>	<b>6.81%</b>	<b>4.94%</b>	<b>-4.22%</b>

INR Crores

- Total revenue for the Quarter stood at INR 118.82 crore representing growth of 10.17% & 36.60% as compared to previous quarter and corresponding last year quarter respectively.
- Completed the de-bottlenecking of the capacity of Performance Chemicals in the month of September 2018 which has increased the annual capacity from 6000 MT to 10000 MT.
- Revenue growth has been due to increase in turnover of Shelf Life Solutions, Blends and Performance Chemicals.
- Gross Margin is impacted due to change in product mix and increase in some raw material prices. Generally there is a lag in pass over of increased costs to the customers.
- Overall performance was also enhanced by currency gains in the Quarter.


# Subsidiary Operations – CFS Mexico



INR Crores

- Manufactures Blends.
- CFS Mexico covers the business of the subsidiaries in Mexico, Peru, Guatemala, Colombia & Republic of Dominic.
- Value of EBITDA has been maintained over last quarter even though gross margin was impacted due to change in product mix as well as increase in certain raw material prices.
- There is a lag in passing on increase in costs to the customers.
- Maintains strong profitability in the current quarter.


# Subsidiary Operations – CFS Europe



INR Crores

- CFS Europe manufactures diphenols.
- Annual maintenance shut down was completed in a record time of 10 days which had a slight impact on the revenues.
- Capacity utilization achieved at 82.40%.
- During the quarter, the company has initiated cost reduction program, impact of which will be seen in subsequent quarters.
- Improvement in profit as compared to last quarter

# Subsidiary Operations – CFS Brazil




INR Crores

- Manufactures Blends.
- Revenue has grown due to launch of new products in animal nutrition and better penetration of markets.
- Subsidiary has turned EBITDA positive in current quarter.
- In spite of currency devaluation has shown a better overall performance.




# Subsidiary Operations – CFS Wanglong



INR Crores

- Manufactures Vanillin in China – Manufacturing started at the end of Q2 FY 18.
- Revenues were low due to the seasonality of Vanillin business.
- Turnover is expected to grow as was observed in Q3 and Q4 of FY 18.

## Subsidiary Operations – CFS North America



INR Crores

- Manufactures Blends.
- Subsidiary has launched new products in natural anti-oxidants and animal nutrition, positive impact of these initiatives will be seen in near future.



## Other Operating Subsidiaries



- Business of CFS Argentina and CFS Chile have commenced in the current quarter. CFS Pahang (Singapore) is in the process of registering its products in Malaysia.

## Update on Dahej Project

- With the financial closure of funding required for Dahej Project with subscription of FCCBs amounting to US\$ 15 million from International Finance Corporation on September 14, 2018, the work at the Dahej Project is in full swing.
- Mechanical completion of the project is expected in the month of March 2019 and the commercial production is expected to begin in the first quarter of FY 20.

# Financial Results for Q2 FY 2019



- The Board of Directors, at its meeting in Mumbai on November 6, 2018, approved the financial results for the quarter ended September 30, 2018, which have been filed with the Stock Exchanges.



# Invitation for Investors' Meet



We are pleased to inform that we are conducting an investors' meet instead of an earnings call. The meet is organized on November 16, 2018 Thursday at Oyster, Hotel Sahara Star, Near Domestic Airport, Vile Parle 3.30 pm onwards which will be followed by high tea. In the meet, all our global SBU heads will be present for updating the developments happening across the geographies.

# Disclaimer



This presentation has been prepared by Camlin Fine Sciences Limited (the “Company”) solely for information purposes, without regard to any specific objectives, financial situations or informational needs of any particular person. All information contained has been prepared solely by the Company. No information contained herein has been independently verified by anyone else. This presentation may not be copied, distributed, redistributed or disseminated, directly or indirectly, in any manner. This presentation does not constitute an offer or invitation, directly or indirectly, to purchase or subscribe for any securities of the Company by any person in any jurisdiction, including India and the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. Any person placing reliance on the information contained in this presentation or any other communication by the Company does so at his or her own risk and the Company shall not be liable for any loss or damage caused pursuant to any act or omission based on or in reliance upon the information contained herein. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Further, past performance is not necessarily indicative of future results. This presentation is not a complete description of the Company. This presentation may contain statements that constitute forward-looking statements. All forward looking statements are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated by the relevant forward-looking statement. Important factors that could cause actual results to differ materially include, among others, future changes or developments in the Company’s business, its competitive environment and political, economic, legal and social conditions. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments. Except as otherwise noted, all of the information contained herein is indicative and is based on management information, current plans and estimates in the form as it has been disclosed in this presentation. Any opinion, estimate or projection herein constitutes a judgment as of the date of this presentation and there can be no assurance that future results or events will be consistent with any such opinion, estimate or projection. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such change or changes. The accuracy of this presentation is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the Company. This presentation is not intended to be an offer document or a prospectus under the Companies Act, 2013 and Rules made thereafter, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended or any other applicable law. Figures for the previous period / year have been regrouped wherever necessary to conform to the current period’s / year’s presentation. Total in some columns / rows may not agree due to rounding off. Note: All financial numbers in the presentation are from Audited Financials or Limited Reviewed financials or based on Management estimates.